We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Monoclonal Antibody-based Vaccine Prevents Lassa Fever in Model

By LabMedica International staff writers
Posted on 22 Sep 2017
Print article
Image: A transmission electron micrograph (TEM) of a number of Lassa virus virions adjacent to some cell debris. The virus, a member of the virus family Arenaviridae, causes Lassa fever (Photo courtesy of the CDC).
Image: A transmission electron micrograph (TEM) of a number of Lassa virus virions adjacent to some cell debris. The virus, a member of the virus family Arenaviridae, causes Lassa fever (Photo courtesy of the CDC).
A combination of human monoclonal antibodies was used to protect monkeys infected with Lassa fever virus and prevented infection even when administered as late as eight days after exposure to the virus.

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. The Lassa fever virus infects hundreds of thousands of people every year and is estimated to be fatal in approximately 34% of cases.

Searching for a way to prevent Lassa fever, investigators at The University of Texas Medical Branch (Galveston, USA) tested a combination of human monoclonal antibodies that cross-reacted with the glycoproteins of all four clades of Lassa virus. The mixture of three monoclonal antibodies was administered to nonhuman primates (cynomolgus macaques) beginning up to eight days following exposure to a lethal dosage of Lassa virus.

Results published in the September 4, 2017, online edition of the journal Nature Medicine revealed that the treatment rescued 100% of the monkeys, even when treatment was initiated at advanced stages of disease, including up to eight days after challenge.

“In this study, we tested a combination of three monoclonal antibodies by giving them to nonhuman primates beginning up to eight days following exposure to a lethal amount of Lassa virus,” said senior author Dr. Thomas Geisbert, professor of microbiology and immunology at The University of Texas Medical Branch. “We found that the treatments were well-tolerated and provided 100% protection from Lassa fever. Without treatment, the animals show evidence of the virus in their bodies by day four after exposure.”

The investigators suggested that this treatment could benefit patients with Lassa fever in West Africa who often arrive at the clinic at a late stage of disease.

Related Links:
University of Texas Medical Branch

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.